Tofogliflozin (brand names: Apleway, Deberza) is an SGLT2 inhibitor mainly used in Japan to treat Type 2 Diabetes Mellitus (T2DM), lowering blood sugar by increasing glucose excretion in urine, and also helps with weight loss, blood pressure, and lipids. Beyond diabetes, it shows potential benefits for obesity-related issues like atherosclerosis markers, improving cardiovascular risk factors, and possibly improving heart function, with ongoing research exploring broader applications like preventing certain cancers, though its primary role remains glycemic control. It is grouped under the following drug class(es): Hypoglycemics and SGLT2 inhibitors. Its therapeutic use is listed as antidiabetic agents. The directory classifies it as a commercial API with a synthetic source/manufacturing origin. Other names for this substance include tofogliflozinum, apleway and deberza. Its PubChem CID is 46908929.
Tofogliflozin
| CAS No | 903565-83-3 |
|---|---|
| Molecular Formula | C22H26O6 |
| Molecular Weight | 386.4 g/mol |
| Synonyms | (3S,3'R,4'S,5'S,6'R)-5-[(4-ethylphenyl)methyl]-6'-(hydroxymethyl)spiro[1H-2-benzofuran-3,2'-oxane]-3',4',5'-triol |
Zoho Contact Form
"*" indicates required fields
Frequently Asked Questions
Tofogliflozin (brand names: Apleway, Deberza) is an SGLT2 inhibitor mainly used in Japan to treat Type 2 Diabetes Mellitus (T2DM), lowering blood sugar by increasing glucose excretion in urine, and also helps with weight loss, blood pressure, and lipids.
The listed CAS number is 903565-83-3.
The listed molecular formula is C22H26O6.
The listed molecular weight is 386.4 g/mol.
(3S,3'R,4'S,5'S,6'R)-5-[(4-ethylphenyl)methyl]-6'-(hydroxymethyl)spiro[1H-2-benzofuran-3,2'-oxane]-3',4',5'-triol.
The source lists tofogliflozinum, apleway and deberza.